^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Hairy Cell Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    cladribine (Purinergic receptor P1 agonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

    Published date:
    10/04/2021
    Excerpt:
    Hairy cell leukemia variant (HCLv)...Rituximab concurrent with cladribine (CDAR)...We report final results of a phase II study of CDAR for patients with HCLv. Twenty patients with 0-1 prior courses of cladribine and/or rituximab, including 8 previously untreated, received cladribine 0.15 mg/kg days 1-5 with 8 weekly rituximab doses 375 mg/m2. Patients received a 2nd rituximab course ≥6 months after cladribine...Five patients with TP53 mutations had shorter PFS (median: 36.4 months vs unreached, p=0.0024) and OS (median: 52.4 months vs unreached, p=0.032).
    DOI:
    https://doi.org/10.1182/bloodadvances.2021005039